Journey Medical (DERM) Insider Neil Herskowitz Buys 10,000 Shares

Neil Herskowitz added to his holdings by purchasing 10,000 shares of DERM on June 25, 2026. This insider transaction is part of a broader trend of buying activity within the company.

Insider Buying and Selling at Journey Medical Corporation

On June 25, 2026, Neil Herskowitz bought 10,000 shares of DERM. Other insiders, such as Justin Adam Smith and Michael Cooper Pearce, also acquired 10,000 shares each on the same day. Earlier, on April 22, 2026, CFO Joseph Benesch and COO Ramsey Alloush made significant purchases, acquiring 28,907 and 62,795 shares, respectively.

Other Institutional Activity in DERM

Wasatch Advisors LP increased its stake in DERM by 817,095 shares, bringing its total to 2,133,370 shares valued at approximately $10,005,505. Tang Capital Management LLC, however, reduced its holdings by 244,596 shares, ending with 1,610,000 shares worth about $7,550,900. Vanguard Capital Management LLC opened a new position with 1,082,080 shares valued at $5,074,955. BlackRock, Inc. increased its stake by 253,078 shares, totaling 972,862 shares valued at $4,562,724. Opaleye Management Inc. slightly trimmed its holdings by 15,000 shares, maintaining 960,000 shares worth $4,502,400.

Analysts Set New Price Targets

On March 26, 2026, HC Wainwright & Co. reiterated its buy rating for DERM with a price target of $13.0. The consensus among analysts is a buy rating, with the average target price set at $13.0 based on multiple opinions.

Bottom Line

Neil Herskowitz's recent purchase of DERM shares highlights ongoing insider interest in the company. Institutional investors are also actively adjusting their positions, reflecting varying levels of confidence. Analysts maintain a positive outlook, with reiterated buy ratings and price targets suggesting potential growth. As always, it's important to remember that insider transactions are disclosed after the fact and may not predict future stock performance.